http://www.evrs.eu/medias/2008/congress/Intravitreal-Bevacizumab-in-Retinopathy-of-Prematurity:-30-Months-Follow-Up.-Will-we-Change-our-Way-of-Treating-ROP.flv Maria Ana Martinez-Castellanos, Jose Luis Guerrero-Naranjo, J. Gerardo Garcia-Aguirre, Virgilio Morales-Canton, Omar Honerlage-Merino, R.V. Paul Chan, Hugo Quiroz-Mercado Advantages: We present a treatment with antiangiogenic therapy for retinopathy of prematurity with good outcome...

Read More